[Meta] the survodutide rule is doing its job and people should stop complaining
Genuinely asking, not being difficult.
Everyone in c/intlshipping repeats that biopsy is important. I believe it, but I have never seen anyone show why, and when I search I get 17 threads of people agreeing with each other.
Is there a paper? Is there a measurement? Or is this one of those things that is true because it has been repeated since 2023?
I am not trying to be the "source?" guy. I would just like a source.
best — the order this archive was captured in
Stalled for 3 weeks, changed nothing, and it started moving again on week 34.
Hepatic fat or MASH or what?
the MASH indication changes the risk calculus
Stalled for 3 weeks, changed nothing, and it started moving again on week 26.
MASH claims need the trial and the biopsy endpoint
the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1
Phase 20 or 15?
phase 6 data is interesting, phase 12 will be different
not approved, descriptive posts only
This is correct. Do not generalise from tirzepatide.
not approved, descriptive posts only
glucagon co-agonism has a different safety story
Which trial arm?
the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1
Sceptical. If this were true we would see it reflected in the data and we do not.
- 1Phase 20 or 15?10 comments in this branch · started by u/incretin_ivy
- 2Stalled for 3 weeks, changed nothing, and it started moving again on week 34.7 comments in this branch · started by u/preservative_free_p